靶向T辅助细胞亚群分化细胞因子的生物制剂有效治疗小鼠抗髓过氧化物酶肾小球肾炎
该研究在小鼠抗髓过氧化物酶(MPO)肾小球肾炎模型中,通过肾脏CD4+ T细胞细胞因子基因表达确定Th17早期、Th1晚期的双相参与模式,并比较野生型、Th17缺陷和Th1缺陷小鼠的自身免疫和肾小球肾炎表现,最后用中和性单克隆抗体验证治疗潜力。结果表明靶向IL-23p19减轻早期Th17主导的疾病,靶向IL-12p35减轻晚期Th1主导的疾病,而抗IL-12p40单抗对早期和晚期均有效。
要点
- 抗MPO肾小球肾炎中Th17早期为主,Th1晚期为主。
- Th17缺陷小鼠早期抗MPO自身免疫显著减轻。
- 抗IL-12p40单抗对早期和晚期均有效。
核心结论
- 通过肾脏CD4+ T细胞细胞因子基因表达确定抗MPO肾小球肾炎中主导的T辅助细胞分化亚群,可实现有效的分期单克隆抗体治疗。
研究设计与样本
- 研究采用小鼠抗MPO肾小球肾炎模型,通过定量肾脏CD4+ T细胞基因表达和淋巴结淋巴细胞细胞因子产生确定T辅助亚群的时间参与。
- 比较野生型、Th17缺陷和Th1缺陷小鼠的系统性抗MPO自身免疫和肾小球肾炎。
- 使用中和性单克隆抗体靶向IL-23p19、IL-12p35和IL-12p40评估治疗潜力。
主要发现
- Th17细胞因子(IL-17A和IL-6)快速升高但随自身免疫成熟而下降,Th1细胞因子(IL-12和TNF)占主导。
- 早期,Th1缺陷小鼠的自身免疫和肾小球肾炎与野生型相似,而Th17缺陷小鼠的抗MPO自身免疫显著减轻。
- 晚期,Th1缺陷小鼠自身免疫减轻并免受抗MPO肾小球肾炎。
- 靶向IL-23p19减轻早期Th17主导的抗MPO自身免疫和肾小球肾炎,但不减轻晚期疾病。
- 靶向IL-12p35减轻晚期Th1主导的抗MPO自身免疫和肾小球肾炎,但不减轻早期自身免疫或肾小球肾炎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-myeloperoxidase nephritogenic autoimmunity induces severe glomerulonephritis. To assess the therapeutic potential of monoclonal antibodies targeting T helper (Th) subset differentiation determining cytokines, we studied a murine model of anti-myeloperoxidase glomerulonephritis. The temporal participation of T helper subsets was determined by quantitating gene expression of CD4+ T-cells isolated from nephritic kidneys and cytokine production by lymphocytes from nodes draining myeloperoxidase immunization sites. Th17 cytokines (IL-17A and IL-6) rose rapidly but declined as autoimmunity matured when Th1 cytokines (IL-12 and TNF) predominated. Therefore, T helper subset participation in anti-myeloperoxidase autoimmunity is biphasic, with Th17 early and Th1 late. To confirm the functional relevance of this biphasic pattern, we compared systemic anti-myeloperoxidase autoimmunity in wild type, Th17 deficient and Th1 deficient mice. Early, Th1 deficient mice developed similar autoimmunity and glomerulonephritis to wild type mice. However, Th17 deficient mice had significantly reduced anti-myeloperoxidase autoimmunity. In late autoimmunity, Th1 deficient mice developed reduced autoimmunity and were protected from anti-myeloperoxidase glomerulonephritis. The therapeutic potential of these findings were demonstrated by neutralizing monoclonal antibodies. Targeting IL-23p19 attenuated early Th17 dominated anti-myeloperoxidase autoimmunity and glomerulonephritis but not late phase disease. Targeting IL-12p35 attenuated late phase Th1 dominated anti-myeloperoxidase autoimmunity and glomerulonephritis but not early autoimmunity or glomerulonephritis. Targeting both T helper subsets with an anti-IL-12p40 monoclonal antibody was effective during both early and late phases of anti-myeloperoxidase glomerulonephritis. Thus, definition of dominant T helper differentiating subsets in anti-myeloperoxidase glomerulonephritis by renal CD4+ T-cell cytokine gene expression allows effective proper phase monoclonal antibody treatment of anti-myeloperoxidase glomerulonephritis.
引用
- Gan PY, Chan A, Ooi JD, et al. Biologicals targeting T helper cell subset differentiating cytokines are effective in the treatment of murine anti-myeloperoxidase glomerulonephritis. Kidney Int. 2019. PMID: 31443998. doi:10.1016/j.kint.2019.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。